Abstract: Provided are near-infrared nerve-sparing fluorescent compounds, compositions comprising them, and methods of their use in medical procedures.

Abstract: The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the treatment of cancers.

Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.

Abstract: The disclosure features crystalline forms of Ras inhibitors, pharmaceutical compositions thereof, and their uses in the treatment of cancers.

Abstract: The present invention is related to novel crystalline polymorph. Form-N of Lurbinectedin and process for preparation of Lurbinectedin.

Abstract: Disclosed are a crystal form of a RIPK1 inhibitor, an acid salt thereof, and a crystal form of an acid salt thereof. The crystal form of the RIPK1 inhibitor, the acid salt thereof, and the crystal form of the acid salt thereof have advantages of good stability and low hygroscopicity, and same have good pharmaceutical prospects.

Abstract: Composition and methods of using potassium mixtures from distillate residue, bottoms material and/or waste potassium mixtures produced in natural fats and oils processing plants potassium mixtures are disclosed. Applications include: fertilizer and fertilizer additives, freeze conditioning, dust control, coating oil, wastewater treatment, microbial food source, chemical degradation, and fire prevention.

Abstract: An MOF film comprising an MOF and an organic scaffold. The MOF is attached to the organic scaffold by hydrogen bonds. The MOF film may be a PCMOF and/or HKUST and may have proton conductive properties. The MOF film may comprise a coordinated metal. The organic scaffold may comprise cellulose material. The MOF film may be free standing without physical support from another material or structure, may be formed into shapes, and may be bent or folded. The MOF film may comprise an MOF and an organic scaffold at different weight ratios.

Abstract: Provided are organometallic compounds comprising as metal at least one of the coin metals Au, Ag, and Cu and further a ligand comprising a 5-membered heterocyclic ring which is fused to a 6-membered aromatic ring and also fused to a 5- or 6-membered carbocyclic or heterocyclic ring or fused ring system. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

Abstract: The present invention provides a metal alkoxide compound represented by the following general formula (1), a thin-film-forming raw material containing the same, and a thin film production method of forming a metal-containing thin film using the raw material:

Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

Abstract: The present disclosure provides an organic compound represented by any of the following general formulae [1-1] and [1-2]: where R1 to R8 are each selected from a hydrogen atom, a halogen atom, a deuterium atom, and substituted or unsubstituted alkyl, alkoxy, amino, aryl, aryloxy, heteroaryl, cyano, and silyl groups, R4 may be combined with Ar1 to form a ring, Ar1 is a substituted or unsubstituted aryl or heterocyclic group, Ar2 is a substituted or unsubstituted divalent arylene group or divalent linking group, the divalent linking group being derived from a heterocyclic group, X1 and X2 are each selected from an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom, and a nitrogen atom having substituent Z, and the substituent Z is a hydrogen atom, a deuterium atom, or a substituted or unsubstituted alkyl, aryl, or heteroaryl group.

Abstract: The present application relates to substituted dyes containing bis-boron fused heterocycles and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Abstract: An improved catalyzed reaction of silicon metal with alcohol is provided for the formation of alkoxysilanes, particularly trialkoxysilanes. The Direct Synthesis reaction of silicon metal and alcohol employs a catalytically effective amount of a copper-aluminum alloy as a catalyst precursor and further benefits from an effective catalyst-promoting amount of a catalyst promoter.

Abstract: A process for preparing cyanoethyltrimethoxysilane is performed via transesterification of cyanoethyltriethoxysilane with methanol in the presence of a catalyst. The cyanoethyltrimethoxysilane is useful as an adhesion promoter, a coupling agent, or a crosslinker. The cyanoethyltrimethoxysilane may be formulated in a polyorganosiloxane sealant composition.

Abstract: Multi-nuclear tin compounds and related methods are provided. A method comprises obtaining a mono-substituted tin (IV) amide compound; obtaining a silanol compound; and contacting the mono-substituted tin (IV) amide compound with the silanol compound to form a multi-nuclear tin compound. A composition comprises a multi-nuclear tin compound.

Abstract: One aspect of the present invention is a method for producing a compound represented by following general formula (1), the method being characterized by including a step of mixing ethylene, a compound represented by following general formula (2), and a compound represented by following general formula (3) to react with each other to give a compound represented by following general formula (4): A1 to A4 each independently represent an aromatic group, and Z1 and Z2 each independently represent an oxygen atom, a sulfur atom, or a borane (BH3), Z3 represents an oxygen atom or a sulfur atom, n1 to n3 each independently represent 0 or 1, and X represents a halogen atom.

Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.

Abstract: The Invention relates to a simple two-step method of making highly pure compounds of formula 1a with n being 1 or 2 and M being ruthenium or molybdenum and R being a linear or branched alkyl with 1 to 8 carbon atoms or a cyclic alkyl group with 3 to 9 carbon atoms from starting materials readily available.

Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.

Abstract: The present invention relates to a method for preparing cyclic guanosine-3?, 5?-monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: A steroidal compound, a preparation method therefor and an application thereof. On one hand, provided are a compound represented by formula I, a preparation method therefor, and an application thereof in a method for separating and purifying lanosterol; on the other hand, provided is the method for separating and purifying lanosterol. The method is simple to operate, stable in process, high in productivity and low in cost, and the obtained lanosterol has high purity and can meet medical application thereof.

Abstract: The present disclosure relates to polycyclic (e.g., fused tetracyclic) liver X receptor (LXR) modulators, synthetic methods for preparing such LXR modulators, and methods of using such LXR modulators to treat a disease or condition that would benefit from LXR modulation. Exemplary compounds have quaternary centers at C9 and C13 and a substituted sulfonamide moiety at C16.

Abstract: Disclosed herein are methods for making a poptoid using green solvents such as ethyl acetate, DMSO and/or mixtures thereof. Methods using an acylation solvent that is DMSO or EIOAc or mixtures thereof as well as methods using an acylation wash solvent comprising DMSO wherein the DMSO is greater than 30% v/v are described.

Abstract: The present invention relates to a separation and quantification method of a non-ionic surfactant in a composition comprising polypeptide and non-ionic surfactant by using a zwitterionic hydrophilic interaction liquid chromatography (ZIC-HILIC).

Abstract: The invention relates to a method of purifying a heteromultimeric Fc domain-containing polypeptide, wherein the method comprises the following steps in the indicated order: providing a sample comprising the heteromultimeric Fc domain-containing polypeptide and one or more mispaired variants thereof; contacting a protein A chromatography matrix with the sample and binding the heteromultimeric Fc domain-containing polypeptide to the protein A chromatography matrix; contacting the protein A chromatography matrix with a wash solution, wherein the wash solution comprises octanoate; contacting the protein A chromatography matrix with an elution solution; and collecting an eluate comprising the heteromultimeric Fc domain-containing polypeptide. The invention further relates to the use of a buffer in said method, to a kit for performing said method, and to an eluate obtained by said method.

Abstract: An automated end-to-end continuous purification system for the manufacture of therapeutic proteins to reduce complexity of manual process operations and minimize physical space requirements, wherein the system comprises a plurality of purification stages operated simultaneously in a series.

Abstract: Certain aspects of this disclosure are generally related to methods for separating a plurality of particles from a fluid. In some embodiments, the fluid comprises one or more polypeptides and a plurality of particles. In some embodiments, the method comprises at least partially denaturing a polypeptide in the fluid to form a denatured polypeptide. In some embodiments, the method comprises separating a mixture of the denatured polypeptide and at least 10% of a plurality of particles from the fluid. Without wishing to be bound by any particular theory, the denaturation of the polypeptide in the fluid may allow for some of the plurality of particles to associate with the denatured polypeptide, and/or agglomerate with the denatured polypeptide. The mixture comprising the denatured polypeptide and the plurality of particles may settle (e.g., precipitate) in the fluid and may therefore be separated from the fluid.

Abstract: An apparatus for refining proteins or other biomolecules in biological compositions, such as for separation of proteins from milk, whey, blood plasma, fermentation broth, or similar.

Abstract: Antimicrobial peptoids, compositions thereof, and methods of use. Antimicrobial peptoids or compositions thereof may be used to treat or prevent a fungal infection in a vertebrate. Antimicrobial peptoids or compositions thereof may be used to treat or prevent a fungal infection in a plant.

Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

Abstract: Embodiments of the present disclosure pertains to one or more novel peptoids, derivatives thereof, multimers thereof, and combinations thereof. The peptoids may be suitable for use in treating or preventing a cancer in a subject, detecting a cancer in a subject, or as research and development tools. Further embodiments pertain to methods of inhibiting the growth of cancer cells by exposing the cancer cells to the peptoids. Additional embodiments of the present disclosure pertain to methods of treating or preventing a cancer in a subject by administering the peptoids to the subject. Further embodiments pertain to methods of detecting cancer in a subject by exposing cells susceptible of being cancerous to the peptoids, detecting the presence or absence of vimentin associated with cells susceptible of being cancerous, and correlating the presence or absence of the vimentin to the presence or absence of the cancer in the subject.

Abstract: A peptide as represented by general formula (I), a stereoisomer thereof, a mixture of the stereoisomer, or a cosmetically acceptable salt or pharmaceutically acceptable salt thereof, or a cosmetic composition or pharmaceutical composition thereof, and an application thereof for treatment or care of a disorder, an illness, or a disease of the skin or mucosa.

Abstract: The present invention relates to a cathepsin inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I) wherein (X1) is an amino acid selected from K, L, F and M; (X2) is an amino acid selected from L, A, D, E, F, G, H, I, K, M, N, S, W, Y, Q and R; (X3) is an amino acid selected from R, A and L; (X4) is an amino acid selected from M, I, K, V and Y; (X5) is an amino acid selected from P, A, I, L, V, W and Y; (X6) is an amino acid selected from K, A, E, F, G, I, L, M, N, Q, S, T, V, W, Y and Q; (X7) is an amino acid selected from D, A, E, F, G, I, L, M, N, P, T, V, W, Y, Q and R; and (Y) is a Michael acceptor.

Abstract: The present invention relates to a novel peptide compound or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are compositions and methods suitable for treating coronavirus infections. More particularly, disclosed is a proteinaceous agent that prevents or inhibits the replication of a SARS-CoV virus, including a SARS-CoV-2 virus. Also disclosed is the use of these agents and molecules for treating or preventing a coronavirus infection (including a SARS-CoV-2 infection) in a subject.

Abstract: The present invention relates to novel bicyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Abstract: Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, in particular diseases or conditions associated with cellular injury or cell death, such as organ injury or organ failure, which can be caused by a number of different reasons, such as ischemia or ischemia reperfusion injury, toxins, infection or mechanical trauma.

Abstract: Glycopeptides comprising a peptide that is covalently linked to one or more saccharides. The glycopeptides of the invention have a significantly reduced VPAC2 receptor agonist activity compared to a native PACAP1-27 or PACAP1-38 while maintaining a good PAC1 and/or VPAC1 receptor agonist activity. In particular, the peptide portion of the glycopeptides of the invention has from about 20 to about 25 amino acid residues, and the saccharide moiety portion of the glycopeptides of the present invention comprises from 1 to about 8 carbohydrates. The present invention also discloses methods for using the glycopeptides of the invention in treating various neurodegenerative diseases.

Abstract: gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.

Abstract: The present disclosure relates generally to modified adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.

Abstract: The present inventors confirmed that when a brazzein expression recombinant vector for high expression of brazzein in Saccharomyces cerevisiae was prepared and a S. cerevisiae strain Y2805 was transformed with the recombinant vector, the expression level of brazzein was particularly high, thereby completing an optimal expression system for mass-producing brazzein. Further, when the brazzein expression system is cultured under the optimal culture conditions according to the present invention, the amount of brazzein produced is further increased, the purification process is simple, and costs are reduced. Therefore, it is expected that the brazzein expression system according to the present invention can be widely used for mass-producing and commercializing brazzein, which is a sweet protein.

Abstract: Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.

Abstract: Masking domains and masked antibodies comprising masking domains are provided. In some embodiments, masked antibodies comprising the masking domains demonstrate minimal aggregation and low potential for immunogenicity. In various embodiments, masked antibodies comprising the masking domains may be used in therapeutic treatment.

Abstract: Disclosed are compounds, compositions, uses and methods using inhibitors of the CIP2A-TOPBP1 complex or agents that inhibit phosphopeptide recognition of TOPBP1 BRCT7/8, for treatment of a cancer associated with or characterized by a homologous recombination (HR) deficiency or treatment of cancer cells having HR deficiency.

Abstract: Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor ? chain (“ortho-IL-21R?”) that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21R?, wherein the ortho-IL-21R? binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

Abstract: Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.